반응식
FC(F)(F)S(O[C:7]1[CH:15]=[CH:14][C:13]([C:16]2[N:17]([C:32]([O:34][C:35]([CH3:38])([CH3:37])[CH3:36])=[O:33])[C:18]3[C:23]([CH:24]=2)=[CH:22][C:21]([CH2:25][N:26]2[CH2:31][CH2:30][CH2:29][CH2:28][CH2:27]2)=[CH:20][CH:19]=3)=[C:12]2[C:8]=1[CH2:9][NH:10][C:11]2=[O:39])(=O)=O.[C:42](=[O:45])([O-])[O-].[K+].[K+].O>C(COC)OC>[OH:45][C:42]1[C:14]([CH3:13])=[CH:15][C:7]([C:7]2[CH:15]=[CH:14][C:13]([C:16]3[N:17]([C:32]([O:34][C:35]([CH3:38])([CH3:37])[CH3:36])=[O:33])[C:18]4[C:23]([CH:24]=3)=[CH:22][C:21]([CH2:25][N:26]3[CH2:31][CH2:30][CH2:29][CH2:28][CH2:27]3)=[CH:20][CH:19]=4)=[C:12]3[C:8]=2[CH2:9][NH:10][C:11]3=[O:39])=[CH:8][C:12]=1[CH3:11]참가 물질
5
반응물 3
생성물 1
시약·촉매·용매 1
실험 절차
In a similar manner to Step 1 of Example 152, 4-trifluoromethanesulfonyloxy-7-[1-(tert-butoxycarbonyl)-5-(piperidinomethyl)indol-2-yl]isoindolinone (80.0 mg, 0.135 mmol) was dissolved in dimethoxyethane (9.6 mL), and the solution was treated with 2,6-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaboran-2-yl)phenol (42.0 mg, 0.168 mmol), [bis(diphenylphosphino)ferrocene]dichloropalladium (5.5 mg, 0.0067 mmol), potassium carbonate (58.0 mg, 0.421 mmol) and water (0.030 mL), followed by purification by preparative thin-layer chromatography (chloroform/methanol=6/1) to obtain 4-(4-hydroxy-3,5-dimethylphenyl)-7-[1-(tert-butoxycarbonyl)-5-(piperidinomethyl)indol-2-yl]isoindolinone (39.1 mg, yield 82%).
후처리
- customfollowed by purification by preparative thin-layer chromatography (chloroform/methanol=6/1)
출처 및 근거
- ORD 기록
- ord-3ec181dc7c3e4892b362258d451bf92d
- 출처 데이터셋
- uspto-grants-2010_06
- 특허 번호
- US07745641B2
연결된 노트
불러오는 중…